AGP Executive Report
Last update: an hour agoCancer Care in China: A phase 2 trial reports adjuvant penpulimab improves disease-free survival in very high-risk clear cell renal cell carcinoma, with manageable safety. Lung Cancer Breakthrough: Kelun-Biotech says sac-TMT plus pembrolizumab met the primary PFS endpoint in PD-L1–negative, nonsquamous NSCLC in a phase 3 trial. Dementia Prevention: A new study maps 14 modifiable dementia risk factors and shows how risk patterns differ across regions, including factors like diabetes, obesity, activity levels, and social isolation. AI Regulation in China: New rules target “emotional dependency” risks from AI companion bots, requiring crisis intervention, limits on excessive use, and user data control. Public Health Response: Chinese experts are heading to Uganda to support the Ebola response, including monitoring transmission risks and expanding testing networks. Urban Resilience: China’s “sponge city” and other nature-based infrastructure approaches are being used to absorb floods, cool neighborhoods, and boost biodiversity. Health Tech Watch: A soft adhesive hydrogel interface is reported to improve long-term wearable monitoring by keeping electrodes stable on skin. Wildlife & Disaster Health: Flooding linked to Typhoon Maysak triggered large-scale snake escapes and raised bite-related health risks, with hospitals increasing venom antidote supplies.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
